financetom
Business
financetom
/
Business
/
Apparel maker HanesBrands' Q2 sales beat estimates, raises full-year outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apparel maker HanesBrands' Q2 sales beat estimates, raises full-year outlook
Aug 7, 2025 4:10 AM

Overview

* HanesBrands ( HBI ) Q2 net sales rise 1.8%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 increases 60%, surpassing analyst estimates, per LSEG data

* Co raises full-year 2025 outlook for net sales, operating profit, and EPS

Outlook

* HanesBrands ( HBI ) expects full-year 2025 net sales of $3.53 bln

* Company projects full-year adjusted EPS of $0.66

* HanesBrands ( HBI ) sees third-quarter net sales at $900 mln

* Company anticipates $35 mln tax expense for full-year 2025

Result Drivers

* COST SAVINGS - Gross margin improvement driven by cost savings and productivity initiatives, per CEO Steve Bratspies

* LOWER INPUT COSTS - Gross profit and margin benefited from lower input costs

* SG&A REDUCTION - Operating profit increase attributed to lower SG&A expenses and disciplined expense management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $991.32 $970 mln

mln (6

Analysts

)

Q2 Beat $0.24 $0.18 (5

Adjusted Analysts

EPS )

Q2 Gross 41.6%

Margin

Q2 Beat $153 mln $136 mln

Adjusted (5

operatin Analysts

g profit )

Q2 41.2%

Adjusted

Gross

Margin

Q2 15.5%

Adjusted

operatin

g Margin

Q2 15.6%

Operatin

g Margin

Q2 $154.66

Operatin mln

g profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the apparel & accessories peer group is "buy."

* Wall Street's median 12-month price target for HanesBrands Inc ( HBI ) is $5.50, about 24.2% above its August 6 closing price of $4.17

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Supernus Pharmaceuticals Insider Sold Shares Worth $1,393,899, According to a Recent SEC Filing
Supernus Pharmaceuticals Insider Sold Shares Worth $1,393,899, According to a Recent SEC Filing
Sep 24, 2025
04:21 PM EDT, 09/24/2025 (MT Newswires) -- Jack A. Khattar, Director, President, CEO, on September 23, 2025, sold 29,513 shares in Supernus Pharmaceuticals ( SUPN ) for $1,393,899. Following the Form 4 filing with the SEC, Khattar has control over a total of 2,146,483 common shares of the company, with 1,140,883 shares held directly and 1,005,600 controlled indirectly. SEC Filing:...
H.B. Fuller Fiscal Q3 Adjusted Earnings Rise, Revenue Falls
H.B. Fuller Fiscal Q3 Adjusted Earnings Rise, Revenue Falls
Sep 24, 2025
04:20 PM EDT, 09/24/2025 (MT Newswires) -- H.B. Fuller ( FUL ) reported late Wednesday fiscal Q3 adjusted earnings of $1.26 per diluted share, up from $1.13 a year ago. Analysts polled by FactSet expected $1.24. Revenue for the quarter ended Aug. 30 was $892.0 million, down from $917.9 million a year earlier. Analysts surveyed by FactSet expected $895.8 million....
Steelcase Fiscal Q2 Adjusted Earnings, Revenue Rise
Steelcase Fiscal Q2 Adjusted Earnings, Revenue Rise
Sep 24, 2025
04:22 PM EDT, 09/24/2025 (MT Newswires) -- Steelcase ( SCS ) reported late Wednesday fiscal Q2 adjusted earnings of $0.45 per diluted share, up from $0.39 a year ago. Four analysts polled by FactSet expected $0.37. Revenue for the quarter ended Aug. 29 was $897.1 million, up from $855.8 million a year earlier. Four analysts surveyed by FactSet expected $873.6...
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours
Sep 24, 2025
04:20 PM EDT, 09/24/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said late Wednesday it plans to issue $110 million of convertible senior notes due 2031 in a private placement, subject to market conditions. KalVista plans to give initial purchasers an option to buy up to an additional $15 million of notes. Net proceeds from the planned offering will...
Copyright 2023-2026 - www.financetom.com All Rights Reserved